학술논문
Cytokines, brain proteins, and growth factors in acute stroke patients: A pilot study.
Document Type
Academic Journal
Author
Zafar A; Department of Neurology, University of Toronto, Toronto, Canada.; Farooqui M; Department of Neurology, University of Iowa, Iowa City, Iowa.; Ikram A; Department of Neurology, University of New Mexico, Albuquerque, New Mexico.; Suriya S; Department of Neurology, University of New Mexico, Albuquerque, New Mexico.; Kempuraj D; Department of Neurology, University of Missouri, Columbia, Missouri.; Khan M; Department of Neurology, University of Tennessee, Memphis, Tennessee.; Tasneem N; Department of Neurology, University of Iowa, Iowa City, Iowa.; Qaryouti D; Department of Neurology, University of New Mexico, Albuquerque, New Mexico.; Quadri S; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, United States.; Adams HP; Department of Neurology, University of Iowa, Iowa City, Iowa.; Ortega-Gutierrez S; Department of Neurology, University of Iowa, Iowa City, Iowa.; Leira E; Department of Neurology, University of Iowa, Iowa City, Iowa.; Zaheer A; Department of Neurology, University of Missouri, Columbia, Missouri.
Source
Publisher: Scientific Scholar LLC Country of Publication: United States NLM ID: 101535836 Publication Model: eCollection Cited Medium: Print ISSN: 2229-5097 (Print) Linking ISSN: 21527806 NLM ISO Abbreviation: Surg Neurol Int Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2229-5097
Abstract
Background: Immunomodulation and cell signaling involve several cytokines, proteins, and other mediators released in response to the trauma, inflammation, or other insults to the central nervous system. This pilot study is part of the registry designed to evaluate the temporal trends among these molecules after an acute ischemic stroke (AIS) in patients.
Methods: Twelve AIS patients were enrolled within 24 hours of the symptoms onset. Two sets of plasma samples were collected: First at admission and second at 24 hours after admission. Cytokines/chemokines and other inflammatory molecules were measured using multiplex assay kit.
Results: An increased trend in IL-6 (22 vs. 34 pg/ml), IL-8/CXCL8 (87 vs. 98 pg/ml), MMP-9 (16225 vs. 18450 pg/ml), and GMF-β (999 vs. 3739 pg/ml) levels was observed overtime after an AIS. Patients ≤60 years had lower levels of plasma MCP-1/CCL2 (50-647 vs. 150-1159 pg/ml), IL-6 (9-25 vs. 20-68 pg/ml), and IL-8 (30- 143 vs. 72-630 pg/ml), when compared with patients >60 years old.
Conclusion: Cytokines/chemokines and other inflammatory mediators play an important role in the pathogenesis of stroke in addition to mediating poststroke inflammation. Further research is needed to evaluate and characterize the cumulative trends of these mediators for the clinical prognosis or as surrogate biomarkers.
Competing Interests: There are no conflicts of interest.
(Copyright: © 2021 Surgical Neurology International.)
Methods: Twelve AIS patients were enrolled within 24 hours of the symptoms onset. Two sets of plasma samples were collected: First at admission and second at 24 hours after admission. Cytokines/chemokines and other inflammatory molecules were measured using multiplex assay kit.
Results: An increased trend in IL-6 (22 vs. 34 pg/ml), IL-8/CXCL8 (87 vs. 98 pg/ml), MMP-9 (16225 vs. 18450 pg/ml), and GMF-β (999 vs. 3739 pg/ml) levels was observed overtime after an AIS. Patients ≤60 years had lower levels of plasma MCP-1/CCL2 (50-647 vs. 150-1159 pg/ml), IL-6 (9-25 vs. 20-68 pg/ml), and IL-8 (30- 143 vs. 72-630 pg/ml), when compared with patients >60 years old.
Conclusion: Cytokines/chemokines and other inflammatory mediators play an important role in the pathogenesis of stroke in addition to mediating poststroke inflammation. Further research is needed to evaluate and characterize the cumulative trends of these mediators for the clinical prognosis or as surrogate biomarkers.
Competing Interests: There are no conflicts of interest.
(Copyright: © 2021 Surgical Neurology International.)